Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategy
Biotech
I-Mab unveils new name, strategy, asset and Hong Kong IPO plans
Less than two years after laying out plans to divest its China operations, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.
Andrea Park
Oct 17, 2025 10:45am
Medidata elevates Amgen vet to lead business strategy
Aug 13, 2025 12:15pm
BMS taps biotech analyst to lead long-term strategy
Jun 13, 2025 11:11am
Annexon, Liminal shrink pipelines to focus on possible homeruns
Jan 9, 2023 11:37am
BridgeBio's CEO on staying alive, 'motherhood and apple pie'
May 26, 2022 5:00am
Medtronic builds out executive team with 4 new hires
Nov 15, 2021 10:20am
